About This Show
AudioAbstracts by ReachMD provides an easy-to-digest distillation of important medical literature in combination with digital linkage to in-depth information supporting the audio synopsis. AudioAbstracts harnesses the ReachMD digital network to broadcast the spoken synopsis and related digital links through its on-air, online, onsite, and mobile distribution network. Combining quick-read audio synopses with links to source material, AudioAbstracts is the smarter, faster way to stay current on medical literature.
Most Recent Episode
DRCR.net Anti-VEGF Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Post-Hoc Analyses
Anti-VEGF Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Post-Hoc Analyses Lee M. Jampol, MD, Adam R. Glassman, MS, Neil M. Bressler, MD, John A. Wells, MD, Allison R. Ayala MS JAMA Ophthalmol. 2016;134(12):1429-1434. doi:10.1001/jamaophthalmol.2016.3698 Abstract Importance: Post-hoc analyses from DRCR.net randomized trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME) might influence interpretation of study results. Objective: To provide additional post-hoc clinically relevant outcomes comparing three anti-VEGF agents for DME Design, Setting, Participants: Post-hoc analysis from a 2-year randomized clinical trial of 660 participants comparing three anti-VEGF treatments in eyes with center-involved DME causing vision impairment. Exposure: Random allocation to intravitreous aflibercept (2.0-mg), bevacizumab (1.25-mg) or ranibizumab (0.3-mg) administered up to monthly based on a structured retreatment regimen. Focal/grid laser was added after 6 months for persistent DME. Main Outcome Measures: Change in visual acuity area under the curve; change in central subfield thickness (CST) within subgroups based on whether an eye received laser treatment for DME during the study Results: For eyes with initial visual acuity (VA) 20/50 or worse, VA improvement was greater with aflibercept than the other agents at one year, but superior only to bevacizumab at the two year visit. VA remained largely ...